TP53 and acute myeloid leukemia: Although studies have shown that the frequency of TP53 mutations is lowest in AML compared to other cancers, AML patients carrying TP53 mutations show shorter survival compared to TP53 wildtype patients in the TCGA data set [2,254,255], underscoring the importance of TP53 in AML pathogenesis and prognosis.